Chemotherapy resistance and retreatment: a dogma revisited.
The prevailing belief in cancer therapy is that retreatment with a given drug after the emergence of resistance is ineffective. Herein, we report several cases in which retreatment with drugs that had failed earlier in the disease trajectory caused renewed tumor regression. The possible biologic underpinnings that might explain this phenomenon are discussed.
Naing
Aung
A
Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston.
Kurzrock
Razelle
R
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure
D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen